- Home
- NIU vs KZIA Comparison
NIU vs KZIA Comparison
Compare NIU & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NIU | KZIA |
|---|---|---|
| Founded | 2014 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.6M | 154.9M |
| IPO Year | 2018 | 2002 |
Fundamental Metrics
Financial Performance| Metric | NIU | KZIA |
|---|---|---|
| Price | $2.55 | $12.35 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.50 | ★ $19.50 |
| AVG Volume (30 Days) | ★ 315.3K | 163.3K |
| Earning Date | 05-18-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.54 | N/A |
| Revenue Next Year | $17.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.93 | $4.86 |
| 52 Week High | $5.67 | $17.40 |
Technical Indicators
Market Signals| Indicator | NIU | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 60.69 | 40.85 |
| Support Level | $2.31 | $11.90 |
| Resistance Level | $3.24 | $14.75 |
| Average True Range (ATR) | 0.14 | 1.07 |
| MACD | 0.06 | -0.10 |
| Stochastic Oscillator | 72.11 | 10.77 |
Price Performance
Historical ComparisonAbout NIU Niu Technologies
Niu Technologies designs, manufactures, and sells high-performance electric motorcycles, scooters, bicycles, and kick-scooters. The company has a product portfolio consisting of electric motorcycles, mopeds, and bicycle series, including the NQi, MQi, UQi, FQi series, and others, and micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. The company's principal operations and geographic markets are predominantly in the People's Republic of China. It also generates revenue from Europe and other regions.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.